Novartis is nearing a deal to buy cholesterol-drug maker The Medicines for nearly US$7 billion, in an expensive bid to expand its reach in the lucrative market for heart treatments, reported the Wall Street Journal.
Using a fully diluted share count, the deal is worth about US$9.7 billion, one of the people said.
The acquisition would help Novartis, which has a market value of more than US$200 billion, bulk up in a corner of the health-care market it is already targeting with drugs including its heart-failure treatment Entresto.
The cholesterol drug under development by Medicines, based in Parsippany, N.J., is aimed at patients who aren’t well-treated by older statin pills.
Pairing the Novartis and Medicines therapies would give sales representatives more products to peddle to heart doctors, potentially boosting sales of each.
The Medicines drug is based on relatively new technology that uses the body’s molecular messengers, known as RNA, to turn off genes playing a role in a disease.The technology is known as RNA interference.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Reserve Greenlights Capital One’s $35.3 Billion Acquisition of Discover
Apr 18, 2025 by
CPI
Google to Appeal Partial Ruling in DOJ Antitrust Case
Apr 18, 2025 by
CPI
Indian Ad Agencies Warned Against WhatsApp Discussions After Antitrust Raids
Apr 17, 2025 by
CPI
US Court Ruling Against Google Spurs Fresh Antitrust Tensions in Europe
Apr 17, 2025 by
CPI
AstraZeneca Accused of Stifling Biosimilar Competition for Rare Disease Drug
Apr 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Airline Industry
Apr 10, 2025 by
CPI
Boosting Competition in International Aviation
Apr 10, 2025 by
Jeffrey N. Shane
Reshaping Competition Policy for the U.S. Airline Industry
Apr 10, 2025 by
Diana L. Moss
Algorithmic Collusion in the Skies: The Role of AI in Shaping Airline Competition
Apr 10, 2025 by
Qi Ge, Myongjin Kim & Nicholas Rupp
Competition in U.S. Airline Markets: Major Developments and Economic Insights
Apr 10, 2025 by
Germán Bet